Future of Patent Practice: Balancing Big Firm Mergers and the Boutique Draw

by Dennis Crouch

I saw this morning that Womble Bond Dickinson and Lewis Roca are merging to create firm with 1,300+ lawyers. By my quick count, the new combo will have 150+ US patent attorneys under the WBD brand that the wider-known of the two (especially internationally).  Two other big mergers announced this week - Troutman Pepper and Locke Lord; Ballard Spahr and Lane Powell.   The "Troutman Pepper Locke" merger will result in 1,600+ lawyers, with about 200 lawyers in their IP group (of which about 100 will be "patent attorneys").   The Ballard Spahr merger is also large (750+ lawyers), but Lane Powell's IP practice is fairly small -- likely meaning that Ballard Spahr's patent group (largely based in Atlanta) may end up quite successful if they are able to cross-sell to Lane Powell's clients.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

The Patent Eligibility Restoration Act (PERA) of 2024: From Oz to Earth

by Dennis Crouch

As its name suggests, the Patent Eligibility Restoration Act (PERA) is designed to substantially overturn the Supreme Court's decisions in Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012), and Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014). Together those cases created a firestorm of invalid patents and challenges for the patent office and patent holders alike.  The bipartisan proposal was introduced in the Senate (Coons/Tillis) earlier this term and most recently introduced to the US House of Representatives (Kiley/Peters).   Although Alice and Mayo doctrine created substantial confusion, much of that confusion has now died down in the past decade.* The bigger issue is that it is substantially harder to obtain patents and easier to invalidate issued patents -- particularly in cases where the invention lies in software or diagnostic methods.  This post examines the proposed PERA and its potential impact -- along with providing a bit of data.

* Although the extreme confusion is gone, there is still plenty to go around.  A case in point is the Federal Circuit's September 3, 2024 decision in BBiTV v. Amazon. In that case, the court showed its linguistic flexibility in distinguishing the claimed user interface (deemed ineligible) from those in Core Wireless and Data Engine (deemed eligible).


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Tapping our Full Potential: Nominations for US Council on Inclusive Innovation

by Dennis Crouch

A cornerstone of Dir. Kathi Vidal's tenure as USPTO Director has been a continued focus on inclusivity and diversity in the innovation ecosphere.  In 2024, the USPTO launched a significant initiative to address major disparities in patent participation among underrepresented groups -- with strong support from the Council for Inclusive Innovation (CI2).  CI2 is now seeking nominations for new council members. In addition to highlighting the nomination process, this post provides some critiques on the initiative's approach to fostering a more diverse and dynamic innovation landscape in the United States.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

ITC Patent Jurisdiction: Roku’s Petition and Contreras’ Critique

by Dennis Crouch

Roku, Inc. has asked the Supreme Court to review 2024 Federal Circuit decision affirming the US International Trade Commission's (ITC) finding of a Section 337 violation based on infringement of a TV-remote patent owned by Universal Electronics, Inc. (UEI). US10593196 (method of configuring user interfaces on home theater devices to control other appliances).

The petition focuses on the ITC's "domestic industry" requirement, and the level of nexus required between substantial domestic investment, the scope of the asserted patent, and any articles that embody the patented invention.  The case invites a broader reconsideration of the ITC's role in patent disputes, including its near-automatic issuance of exclusion orders against adjudged infringers.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Policy Considerations: The On-Sale Bar for Secret Processes

by Dennis Crouch

In light of the Federal Circuit's recent decision in Celanese v. ITC, it's worth examining the policy implications of maintaining a strong on-sale bar that extends even to invalidate patents on secret processes when the resulting products have been commercialized. This rule is rooted in pre-AIA jurisprudence and is now affirmed under the AIA.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Family Planning Patent Style: Allergan, Cellect, and the ODP Maze

by Dennis Crouch

Most U.S. utility patents are (or will eventually be) part of a patent family with at least one other U.S. patent. The recent rise in focus on obviousness type double patenting (ODP) has been unnerving to some, especially with the Cellect decision from 2023 that seemed to greatly expand the risk of family members colliding based upon differing expiration dates due to Patent Term Adjustment (PTA).

The Federal Circuit's new ODP opinion in Allergan USA v. MSN Labs, 24-1061 (Fed. Cir. August 13, 2014), provides some major relief to patent portfolio holders, holding that "a first-filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date." This ruling provides a measure of protection for first-filed patents that receive substantial PTA, shielding them from ODP challenges based on their own continuations sharing the same priority date.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Lovevery Argues that APEX Jurisdiction Holding Undermines Anti-Counterfeiting Efforts

by Dennis Crouch

This is my third post about SnapPower (SnapRays) v. Lighting Defense, and the Federal Circuit's holding that patentee's who use Amazon's patent enforcement process (APEX) to block infringing product sales open themselves to personal jurisdiction in the home state of the accused infringer. SnapPower v. Lighting Def. Group, 100 F.4th 1371 (Fed. Cir. 2024). In my view, the Federal Circuit has gone too far with aggressive personal jurisdiction in this case, and the patentee Lighting Defense has petitioned for en banc rehearing on the issue.

Most recently, toy-maker Lovevery has filed an amicus brief supporting en banc review.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Celebrity Names and Trademark Claims: Insights from the Hobbs Winery Case

by Dennis Crouch

The Federal Circuit's recent decision involving Paul Hobbs and Hobbs Winery raises a number of important issues for anyone investing in celebrities or influencers.  In the case, early investors in Hobbs Winery were unable to prevent Mr. Hobbs from using his name in other wine ventures, even though a registered mark on PAUL HOBBS was owned by Hobbs Winery. This case was decided on statutory grounds - with a holding that minority owners in a company are not authorized to bring a TM cancellation to protect a mark held by the company.  This is an important decision because it prevents the TTAB from being used to settle internal corporate management issues.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

The Use of Mandated Public Disclosures of Clinical Trials as Prior Art Against Study Sponsors

By Chris Holman

Salix Pharms., Ltd. v. Norwich Pharms. Inc., 2024 WL 1561195 (Fed. Cir. Apr. 11, 2024)

Human clinical trials play an essential role in the discovery, development, and regulatory approval of innovative drugs, and federal law mandates the public disclosure of these trials. Pharmaceutical innovators are voicing concern that these disclosures are increasingly being used as prior art to invalidate patents arising out of, or otherwise relating to, these trials, in a manner that threatens to disincentivize investment in pharmaceutical innovation. A recent Federal Circuit decision, Salix Pharms., Ltd. v. Norwich Pharms. Inc., illustrates the concern.  In Salix, a divided panel upheld a district court decision to invalidate pharmaceutical method of treatment claims for obviousness based on a clinical study protocol published on the ClinicalTrials.gov. website. The case garnered amicus curiae briefs filed by several innovative pharmaceutical companies in support of the patent owner, Salix Pharmaceuticals.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Obviousness and Pharmaceutical Method of Treatment Claims

by Dennis Crouch

In April 2024, the Federal Circuit issued a significant decision vacating a district court's judgment that Janssen Pharmaceuticals' dosing regimen patent claims were nonobvious. Janssen Pharms., Inc. v. Teva Pharms. USA, Inc., No. 2022-1258 (Fed. Cir. Apr. 1, 2024). The case involved Janson's U.S. Patent No. 9,439,906, which claims methods of treating schizophrenia by administering specific doses of the long-acting injectable antipsychotic paliperidone palmitate.

Teva filed an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Janssen's Invega Sustenna product, which embodies the claimed methods. In the ensuing Hatch-Waxman litigation, Teva stipulated to infringement but challenged the patent on obviousness and indefiniteness grounds. Following a bench trial Judge Cecchi (D.N.J.) rejected Teva's invalidity defenses, and Teva appealed.

On appeal, Judge Prost authored a unanimous opinion affirming the district court's indefiniteness determination but vacating and remanding on obviousness.  Overall, this is a bad case for pharmaceutical formulary patents.

This post focuses on the court's obviousness holding and its potential implications for pharmaceutical method of treatment claims more broadly. I make three key claims. . .


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Two Mandamus Petitions: Transfer Granted, Improper Service Denied

by Dennis Crouch

A Federal Circuit panel recently released a pair of mandamus orders dealing with important civil procedure issues - one granting a petition to transfer venue under 28 USC 1404(a) , the other denying a petition challenging substitute service of process for a foreign defendant.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

A present assignment of future continuation applications

by Dennis Crouch

In Roku, Inc. v. ITC, the Federal Circuit has affirmed determinations by the International Trade Commission (“ITC”) favoring the patent holder Universal Electronics, Inc. (“Universal”). The most interesting part of the case for me is the assignment issue - whether the patents had been properly assigned at the appropriate time. This can become in cases like this because Universal has created a large patent portfolio that all claim back to original priority documents from more than a decade ago. While most of patents are attributable to both joint-inventors, some are only attributable to one or the other.  Here, though the Federal Circuit supported the simple approach of a "hereby assigns" transfer of rights that includes future continuations.  The decision is lacking though because the court does not ground its decision in any particular contract or property tradition.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Sharon Israel, PTO New Chief Policy Officer

Congratulations to Sharon Israel on her new leadership role at the USPTO.  I was happy to learn that Director Vidal has appointed Sharon Israel as its new Chief Policy Officer and Director for International Affairs. Ms. Israel has been a leader of the patent bar for many yeas and will bring tremendous expertise to this important role overseeing the USPTO's policy and international programs.  For the past few years, she has been a partner at Shook Hardy focusing on patent litigation -- primarily on the defense side.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Plagiarism Police come for Winston & Strawn

Hsuanyeh Law Group v. Winston & Strawn, 23-cv-11193 (S.D.N.Y. 2024)

A recent copyright infringement lawsuit filed by small Boston intellectual property boutique Hsuanyeh Law Group PC (HLG) against international giant Winston & Strawn LLP focuses a dividing line that can highlight when copying the work of another firm is permissible.  I believe that Winston & Strawn will eventually prevail based upon a fair use defense, but it is still an embarrassing situation for the firm and attorneys involved.  I hope that they did not overbill the client.  The role of attribution is also receiving increasing focus as attorneys begin to rely more heavily on AI outputs for their legal documents.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

The First Precedential Patent Decision of 2024: Dexcom v. Abbott Diabetes Care

by Dennis Crouch

The U.S. Court of Appeals for the Federal Circuit has begun 2024 [2023] with its first precedential patent decision in DexCom, Inc. v. Abbott Diabetes Care, Inc., 2023-1795 (Fed. Cir. January 3, 2024).  In an opinion by Judge Stoll, the court affirmed a district court decision denying DexCom’s motion for a preliminary injunction. The patentee had requested an order barring Abbott from pursuing its IPR challenges - based upon a forum selection clause that was part of a prior settlement between the parties. Judges Dyk and Hughes were also on the panel.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

The FTC’s Misguided Comments on Copyright Office Generative AI Questions

Guest Post from Professors Pamela Samuelson, Christopher Jon Sprigman, and Matthew Sag

The U.S. Copyright Office published a Notice of inquiry (“NOI”) and request for comments, Artificial Intelligence and Copyright, Docket No. 2023-6 on August 30, 2023, calling for comments from interested parties addressing dozens of questions. The Office’s questions focused on a wide range of issues including the copyright implications of the use of in-copyright works as training data, on the feasibility of licensing such uses, the impact on competition and innovation in AI industries depending on how courts resolved training data copyright issues, the copyrightability of AI outputs, whether new laws regulating generative AI were needed, whether AI developers should be obliged to disclose the sources of their training data, and whether AI outputs should be labeled as such.

The Office received roughly 10,000 comments on October 30, 2023. We, who have been writing and teaching about copyright law and how it has responded to challenges posed by new technologies for decades, were among those who submitted comments, see https://www.regulations.gov/comment/COLC-2023-0006-8854.

After reading and reflecting on comments filed by Federal Trade Commission (FTC), see https://www.regulations.gov/comment/COLC-2023-0006-8630, we decided to file a reply to the FTC’s comments, see https://www.regulations.gov/comment/COLC-2023-0006-10299. Below is the substance of our reply comments explaining why we believe the agency’s comments were ill-informed, misguided, and highly ambiguous.

Substance of the Samuelson, Sprigman, Sag Reply Comments:

We should begin by noting our appreciation for the FTC’s work enforcing both federal antitrust and consumer protection laws and helping to lead policy development in both areas. In our view, the FTC plays a vital role in keeping markets open and honest, and we have long been admirers of the intelligence and energy that the agency brings to that task. More specifically, we recognize the usefulness of examining intellectual property issues through the lenses of competition and consumer protection.

However, in the case of its response to the Copyright Office’s NOI on Artificial Intelligence and Copyright, the FTC has submitted Comments that are unclear and thus open to a variety of interpretations—and possibly to misinterpretations as well. The FTC’s Comments also raise questions about the scope of agency’s authority under Section 5 of the Federal Trade Commission Act, 15 U.S.C. 45, to bring enforcement actions aimed at activities, including those involving the training and use of AI, that might involve copyright infringement—although we would note that the copyright consequences of AI are, as yet, undefined.

We have three principal criticisms of the FTC’s comments:

First, the FTC’s submission is not a model of clarity: indeed, later in these Comments we will focus on a particular sentence from the FTC Comments that is worrisome both for its opacity and for the ways in which it may be interpreted (or misinterpreted) to chill innovation and restrict competition in the markets for AI technologies.

Second, the FTC Comments do not appear to be based on a balanced evidentiary record; rather, the Comments appear largely to reflect views articulated by participants in an Oct. 4, 2023, FTC Roundtable event[1] that featured testimony largely from artists and writers critical of generative AI: 11 of the 12 witnesses appeared to be or to represent individual creators, and one represented open-source software developers who objected to AI training on their code. Not a single witness provided perspectives from technologists who have developed and work with AI agents. Perhaps not surprisingly given the imbalance in the record, the FTC comments do not seem to appreciate the variety of use cases for AI technologies or the broader implications of those technologies for competition policy.

Third, and finally, certain of the FTC’s Comments could, if misunderstood, upset the careful balance that the copyright laws create between private rights to control copyrighted works and public access and use of those works. Upsetting that balance could chill development not only of useful AI technologies, but of a range of new technologies and services that augment consumers’ opportunities to access and use copyrighted works and increase the value of those works to consumers.

In the remainder of these Comments we will focus on a specific sentence from the FTC Comments that illustrates all of these problems.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.